# Temedica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/temedica

- Industry: Software
- Headquarters: Munich, Germany
- Website: www.temedica.com
- Total disclosed funding: $44M
- Latest round: Series B (Aug 26, 2022)
- Investors on record: 5

## About

Temedica GmbH is a German company specializing in AI-driven solutions that enhance commercialization for pharmaceutical firms. Their focus is on real-world insights and patient engagement to optimize healthcare outcomes.Founded in 2016 and headquartered in Munich, Germany, Temedica GmbH focuses on providing AI-powered solutions for the pharmaceutical sector. The company was established by Gloria Seibert, Pd Friedrich, and Tom Feuerstein. Temedica has successfully completed a total of 2 funding deals, with the most recent being a Series B round on August 26, 2022, raising EUR 25 million led by Santo Venture Capital and MIG Verwaltungs AG. The total amount raised by the company stands at EUR 25 million with a current valuation of EUR 67.11 million.Temedica specializes in AI-powered solutions aimed at enhancing the commercialization efforts of pharmaceutical companies. Their core offerings include the Permea Insight Hub, Permea Disease Navigator, and Patient Companion, which collectively facilitate real-world insights, patient engagement, and data-driven decision-making. These products are designed to address challenges such as optimizing brand performance, improving patient adherence, and generating real-world evidence to inform medical and commercial strategies. The client base primarily consists of pharmaceutical companies looking to refine their marketing, sales, and patient engagement strategies. Temedica’s solutions are utilized across various geographical markets, including Europe and North America, where they cater to a diverse range of therapeutic areas, with a significant focus on conditions like multiple sclerosis.Temedica generates revenue through a multi-faceted transaction structure involving B2B partnerships with pharmaceutical companies. Clients typically engage with Temedica through subscription agreements for access to their suite of AI-driven tools and insights. This allows pharmaceutical companies to leverage real-time data for market analysis, patient journey mapping, and adherence solutions. Specific pricing structures for these services are tailored to the individual needs of the clients, based on the complexity and scope of the projects undertaken. Notably, flagship products like the Permea Disease Navigator and Patient Companion are integral to their offerings, driving value through personalized patient insights and engagement strategies.In August 2022, Temedica GmbH raised EUR 25 million in Series B funding, which will be used to further expand its growth in other markets. The company plans to introduce new products aimed at enhancing patient engagement and real-world insights, though specific release dates have not been disclosed. Temedica is targeting expansion into additional European and North American markets to increase its reach within the pharmaceutical industry.

## Funding rounds

- Series B, Aug 26, 2022, $25M — MIG Capital, Santo Venture Capital
- Series B, Jan 24, 2020, $19M — MIG Capital, G+J Digital Ventures, WenVest GmbH, Salvia Développement, Santo Venture Capital

## Investors

- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series B
- G+J Digital Ventures (https://capitalatlas.ai/funds/g-j-digital-ventures) — Series B
- WenVest GmbH — Series B
- Salvia Développement — Series B
- Santo Venture Capital (https://capitalatlas.ai/funds/santo-venture-capital) — Series B